Didemnin B

Drug Profile

Didemnin B

Alternative Names: NSC 325319

Latest Information Update: 01 Aug 2000

Price : $50

At a glance

  • Originator University of Illinois
  • Class Antineoplastics; Depsipeptides
  • Mechanism of Action DNA synthesis inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Brain cancer; Cancer; Malignant melanoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Aug 2000 A phase II study in NHL has been added to the therapeutic trials section
  • 01 Aug 2000 Phase-II clinical trials for Non-Hodgkin's lymphoma in USA (IV-infusion)
  • 07 Oct 1999 Discontinued-II for Malignant melanoma in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top